A5036689689- Prostate Cancer Treatment and Research
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Ovarian cancer diagnosis and treatment
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- PARP inhibition in cancer therapy
- BRCA gene mutations in cancer
- Cancer, Lipids, and Metabolism
- Genetic factors in colorectal cancer
- Radiopharmaceutical Chemistry and Applications
- Endometrial and Cervical Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Cancer survivorship and care
- PI3K/AKT/mTOR signaling in cancer
- Lung Cancer Treatments and Mutations
- RNA modifications and cancer
- Advanced Breast Cancer Therapies
- Prostate Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Multiple Myeloma Research and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Cancer Risks and Factors
- Lymphatic System and Diseases
- Cancer Research and Treatments
Kelowna General Hospital
2009-2024
BC Cancer Agency
2012-2023
University of British Columbia
2008-2023
Interior Health
2012-2020
University of Southampton
2019
Health Net
2014
Juravinski Cancer Centre
2006-2012
Sudbury Regional Hospital
2012
University Health Network
2012
CancerCare Manitoba
2012
Biosynthesis of extragonadal androgen may contribute to the progression castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor biosynthesis, prolongs overall survival among patients with metastatic cancer who have received chemotherapy.We randomly assigned, in a 2:1 ratio, 1195 had previously docetaxel receive 5 mg prednisone twice daily either 1000 acetate (797 patients) or placebo (398 patients). The primary end point was survival. secondary points...
Niraparib is a poly(ADP-ribose) polymerase inhibitor approved in the USA and Europe for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are complete partial response to platinum-based chemotherapy. In pivotal ENGOT-OV16/NOVA trial, dose reduction rate due treatment-emergent adverse event (TEAE) was 68.9%, discontinuation TEAE 14.7%, including 3.3% thrombocytopenia. A retrospective analysis carried out identify...
Mismatch repair deficiency (dMMR) occurs in various cancers, and these tumors are attractive candidates for anti-programmed cell death 1 therapies, such as dostarlimab, a recently approved immune checkpoint inhibitor.
Purpose To evaluate the safety and efficacy of oral everolimus, a mammalian target rapamycin (mTOR) inhibitor, in two different schedules minimally pretreated patients with metastatic breast cancer to explore for possible biologic correlates response. Patients Methods who received no or one prior chemotherapy regimen were entered onto this multicenter, noncomparative, randomized phase II study everolimus 10 mg daily versus 70 weekly; multinomial end points response progression evaluated at 8...
The efficacy of lapatinib versus trastuzumab combined with taxanes in the first-line setting human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (BC) is unknown.The MA.31 trial compared a combination anti-HER2 therapy (lapatinib or trastuzumab) and taxane for 24 weeks, followed by same monotherapy until progression. Stratification was prior (neo)adjuvant therapy, taxane, planned liver metastases. primary end point intention-to-treat (ITT) progression-free...
9 Background: Dostarlimab is a humanized anti–PD-1 monoclonal antibody that binds the PD-1 receptor, blocking interaction with ligands PD-L1 and PD-L2. The ongoing phase 1 GARNET study (NCT02715284) evaluating dostarlimab in pts advanced solid tumors. Here we present safety efficacy data from cohort F. Methods: Cohort F of trial enrolled dMMR or POLEmut non-endometrial tumors; majority were gastrointestinal (GI) origin. Pts must have progressed per blinded independent central review (BICR)...
Clear cell ovarian cancer is an epithelial histotype that less responsive to chemotherapy and carries poorer prognosis than serous endometrioid histotypes. Despite this, patients with these tumors are treated in a similar fashion as all other cancers. Previous genomic analysis has suggested clear cancers represent unique tumor subtype. Here we generated the first whole expression profiling using component of normal surface specimens isolated by laser capture microdissection. All arrays were...
Vitamin E absorption requires the presence of fat; however, limited information exists on influence fat quantity optimal absorption. In present study we compared stable-isotope-labelled vitamin following meals varying content and source. a randomised four-way cross-over study, eight healthy individuals consumed capsule containing 150 mg 2 H-labelled RRR -α-tocopheryl acetate with test meal toast butter (17·5 g fat), cereal full-fat milk semi-skimmed (2·7 fat) water (0 fat). Blood was taken...
LBA671 The full, final text of this abstract will be available at abstract.asco.org 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to 20, issue Journal Clinical Oncology. Onsite Meeting, printed Sunday edition ASCO Daily News.
Exemestane, a steroidal aromatase inhibitor, reduced invasive breast cancer incidence by 65% among 4,560 postmenopausal women randomly assigned to exemestane (25 mg per day) compared with placebo in the National Cancer Institute of Canada (NCIC) Clinical Trials Group MAP.3 (Mammary Prevention 3) trial, but effects on quality life (QOL) were not fully described.Menopause-specific and health-related QOL assessed using four Menopause-Specific Quality Life Questionnaire (MENQOL) domains eight...
PURPOSE Lenvatinib plus pembrolizumab (len + pembro) significantly improved progression-free survival (PFS) and overall (OS) versus chemotherapy in previously treated advanced or recurrent endometrial cancer (aEC) the phase III Study 309/KEYNOTE-775. We report results from III, randomized, open-label European Network of Gynaecological Oncological Trial-en9/LEAP-001 study (ClinicalTrials.gov identifier: NCT03884101 ) that evaluated len pembro first-line aEC. METHODS Patients with stage to IV...
Abstract Purpose: Clusterin is an antiapoptotic protein activated in response to cellular stress. OGX-011 a second-generation antisense oligonucleotide that inhibits clusterin expression. The primary objective of this phase II trial was assess the safety and efficacy combination docetaxel for metastatic breast cancer. Experimental Design: Women with measurable cancer ≤1 chemotherapy regimen were eligible. Three loading doses 640 mg i.v. followed by weekly 75 mg/m2 (every 3 weeks) given. A...